Enovis Co. (NYSE:ENOV) Shares Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company increased its holdings in shares of Enovis Co. (NYSE:ENOV) by 3.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 66,668 shares of the company’s stock after acquiring an additional 2,123 shares during the period. The Manufacturers Life Insurance Company owned approximately 0.12% of Enovis worth $2,870,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Dynamic Technology Lab Private Ltd purchased a new position in Enovis during the third quarter worth approximately $1,050,000. Charles Schwab Investment Management Inc. lifted its position in shares of Enovis by 14.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 600,819 shares of the company’s stock valued at $25,865,000 after buying an additional 73,623 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new stake in Enovis in the 3rd quarter valued at $331,000. Quest Partners LLC purchased a new stake in Enovis in the 3rd quarter worth $741,000. Finally, Mutual of America Capital Management LLC raised its position in Enovis by 5.6% during the third quarter. Mutual of America Capital Management LLC now owns 30,183 shares of the company’s stock worth $1,299,000 after acquiring an additional 1,604 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Trading Down 0.5 %

Shares of Enovis stock opened at $47.63 on Friday. Enovis Co. has a 1-year low of $38.27 and a 1-year high of $65.03. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The stock has a market cap of $2.66 billion, a P/E ratio of -21.75 and a beta of 1.94. The stock’s 50 day simple moving average is $43.70 and its 200-day simple moving average is $44.74.

Enovis (NYSE:ENOV) last issued its earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.11. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The company had revenue of $505.22 million during the quarter, compared to analysts’ expectations of $504.44 million. During the same period in the prior year, the business earned $0.56 EPS. The firm’s quarterly revenue was up 21.0% on a year-over-year basis. Analysts predict that Enovis Co. will post 2.79 EPS for the current fiscal year.

Analyst Ratings Changes

ENOV has been the topic of several research analyst reports. JMP Securities assumed coverage on shares of Enovis in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $62.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $65.00 price target on shares of Enovis in a research note on Thursday, November 7th. Finally, Evercore ISI cut their price objective on Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a research note on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $67.00.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.